Lantern Pharma Inc
LTRN3.550USD
-0.080-2.20%
Handelsschluss 11/05, 16:00（ET）Kurse um 15 Minuten verzögert
38.29MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Lantern Pharma Inc Unternehmen
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform with multiple clinical-stage drug programs. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 60 billion oncology-focused data points and a library of over 200 advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
Lantern Pharma Inc Informationen
BörsenkürzelLTRN
Name des UnternehmensLantern Pharma Inc
IPO-datumJun 11, 2020
CEOMr. Panna L. Sharma
Anzahl der mitarbeiter24
WertpapierartOrdinary Share
GeschäftsjahresendeJun 11
Addresse1920 Mckinney Avenue
StadtDALLAS
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl75201
Telefon19722771136
Websitehttps://www.lanternpharma.com/
BörsenkürzelLTRN
IPO-datumJun 11, 2020
CEOMr. Panna L. Sharma
Führungskräfte von Lantern Pharma Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Maria L. Maccecchini, Ph.D.
Dr. Maria L. Maccecchini, Ph.D.
Independent Director
Independent Director
--
--
Dr. David S. Silberstein, Ph.D.
Dr. David S. Silberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Donald Jeff Keyser, J.D., Ph.D.
Dr. Donald Jeff Keyser, J.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Panna L. Sharma
Mr. Panna L. Sharma
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David R. Margrave, J.D.
Mr. David R. Margrave, J.D.
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
--
--
Dr. Kishor G. Bhatia, Ph.D.
Dr. Kishor G. Bhatia, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Vijay Chandru, Ph.D.
Dr. Vijay Chandru, Ph.D.
Independent Director
Independent Director
--
--
Dr. Lee T. Schalop, M.D.
Dr. Lee T. Schalop, M.D.
Director
Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Maria L. Maccecchini, Ph.D.
Dr. Maria L. Maccecchini, Ph.D.
Independent Director
Independent Director
--
--
Dr. David S. Silberstein, Ph.D.
Dr. David S. Silberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Donald Jeff Keyser, J.D., Ph.D.
Dr. Donald Jeff Keyser, J.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Panna L. Sharma
Mr. Panna L. Sharma
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David R. Margrave, J.D.
Mr. David R. Margrave, J.D.
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
--
--
Dr. Kishor G. Bhatia, Ph.D.
Dr. Kishor G. Bhatia, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Thu, Aug 7
Aktualisiert: Thu, Aug 7
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Bios Equity Partners, LP.
9.96%
Biological Mimetics, Inc
7.82%
Prophase Labs Inc
5.84%
The Vanguard Group, Inc.
3.37%
CM Management, LLC
1.85%
Andere
71.16%
Aktionäre
Aktionäre
Anteil
Bios Equity Partners, LP.
9.96%
Biological Mimetics, Inc
7.82%
Prophase Labs Inc
5.84%
The Vanguard Group, Inc.
3.37%
CM Management, LLC
1.85%
Andere
71.16%
Aktionärstypen
Aktionäre
Anteil
Corporation
13.66%
Venture Capital
10.08%
Investment Advisor
7.31%
Investment Advisor/Hedge Fund
2.15%
Hedge Fund
1.31%
Individual Investor
0.42%
Research Firm
0.12%
Andere
64.95%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
75
2.26M
20.96%
-504.83K
2025Q2
71
3.78M
35.06%
-589.53K
2025Q1
73
4.04M
37.50%
-292.34K
2024Q4
75
4.10M
38.06%
-404.66K
2024Q3
73
4.20M
39.03%
-539.55K
2024Q2
74
4.17M
38.76%
-357.16K
2024Q1
68
4.00M
36.90%
-906.94K
2023Q4
66
4.18M
38.50%
-1.07M
2023Q3
73
4.62M
42.50%
-2.30M
2023Q2
72
4.61M
42.49%
-2.27M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Bios Equity Partners, LP.
1.08M
9.96%
-157.85K
-12.79%
Jun 30, 2025
Biological Mimetics, Inc
844.13K
7.82%
--
--
Jul 23, 2025
Prophase Labs Inc
631.20K
5.84%
--
--
Jul 23, 2025
The Vanguard Group, Inc.
363.72K
3.37%
--
--
Jun 30, 2025
CM Management, LLC
200.00K
1.85%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
91.89K
0.85%
+1.39K
+1.53%
Jun 30, 2025
Renaissance Technologies LLC
90.60K
0.84%
+1.80K
+2.03%
Jun 30, 2025
GWM Advisors LLC
56.51K
0.52%
-3.42K
-5.70%
Jun 30, 2025
Voss Capital LLC
50.00K
0.46%
--
--
Jun 30, 2025
Keyser (Donald Jeffrey PH.D)
45.76K
0.42%
--
--
Jul 23, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: 18 minutes ago
Aktualisiert: 18 minutes ago
Name
Anteil
iShares Micro-Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
Anteil0.01%
Avantis US Small Cap Equity ETF
Anteil0%
DFA Dimensional US Sustainability Core 1 ETF
Anteil0%
Dimensional US Core Equity 1 ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
